-
1
-
-
84959398599
-
Tuberculosis
-
Accessed July 21, 2014
-
World Health Organization (2014) Tuberculosis. Fact Sheet No 104. www.who.int/ mediacentre/factsheets/fs104/en/. Accessed July 21, 2014.
-
(2014)
Fact Sheet
, vol.104
-
-
-
4
-
-
84901039783
-
Treatment of tuberculosis
-
American Thoracic Society; CDC; Infectious Diseases Society of America (RR-11): 1-77, and erratum (2005)
-
American Thoracic Society; CDC; Infectious Diseases Society of America (2003) Treatment of tuberculosis. MMWR Recomm Rep 52(RR-11): 1-77, and erratum (2005) 53: 1203.
-
(2003)
MMWR Recomm Rep
, vol.52
, Issue.53
, pp. 1203
-
-
-
6
-
-
84959398600
-
-
TB Alliance Interactive Portfolio Available at ccessed November 24 2015
-
TB Alliance Interactive Portfolio (2015) PaMZ. Available at www.tballiance.org/portfolio/ regimen/pamz. Accessed November 24, 2015.
-
(2015)
PaMZ.
-
-
-
7
-
-
0032189757
-
Clinical applications of quinolones
-
Hooper DC (1998) Clinical applications of quinolones. BiochimBiophys Acta 1400(1-3): 45-61.
-
(1998)
BiochimBiophys Acta
, vol.1400
, Issue.1-3
, pp. 45-61
-
-
Hooper, D.C.1
-
8
-
-
0035866965
-
Mechanisms of action of antimicrobials: Focus on fluoroquinolones
-
Hooper DC (2001) Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis 32(Suppl 1): S9-S15.
-
(2001)
Clin Infect Dis
, vol.32
, pp. S9-S15
-
-
Hooper, D.C.1
-
9
-
-
21844443566
-
The quinolones: Past, present, and future
-
Andriole VT (2005) The quinolones: Past, present, and future. Clin Infect Dis 41(suppl 2): S113-S119.
-
(2005)
Clin Infect Dis
, vol.41
, pp. S113-S119
-
-
Andriole, V.T.1
-
10
-
-
74049088254
-
Quinolones: Action and resistance updated
-
Drlica K, et al. (2009) Quinolones: Action and resistance updated. Curr Top Med Chem 9(11): 981-998.
-
(2009)
Curr Top Med Chem
, vol.9
, Issue.11
, pp. 981-998
-
-
Drlica, K.1
-
11
-
-
77954187741
-
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs
-
Pommier Y, Leo E, Zhang H, Marchand C (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol 17(5): 421-433.
-
(2010)
Chem Biol
, vol.17
, Issue.5
, pp. 421-433
-
-
Pommier, Y.1
Leo, E.2
Zhang, H.3
Marchand, C.4
-
12
-
-
84898948830
-
Mechanism of quinolone action and resistance
-
Aldred KJ, Kerns RJ, Osheroff N (2014) Mechanism of quinolone action and resistance. Biochemistry 53(10): 1565-1574.
-
(2014)
Biochemistry
, vol.53
, Issue.10
, pp. 1565-1574
-
-
Aldred, K.J.1
Kerns, R.J.2
Osheroff, N.3
-
13
-
-
0035042602
-
Type II topoisomerases as targets for quinolone antibacterials: Turning Dr. Jekyll into Mr. Hyde
-
Anderson VE, Osheroff N (2001) Type II topoisomerases as targets for quinolone antibacterials: Turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des 7(5): 337-353.
-
(2001)
Curr Pharm Des
, vol.7
, Issue.5
, pp. 337-353
-
-
Anderson, V.E.1
Osheroff, N.2
-
14
-
-
38649088911
-
Quinolone-mediated bacterial death
-
Drlica K, Malik M, Kerns RJ, Zhao X (2008) Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52(2): 385-392.
-
(2008)
Antimicrob Agents Chemother
, vol.52
, Issue.2
, pp. 385-392
-
-
Drlica, K.1
Malik, M.2
Kerns, R.J.3
Zhao, X.4
-
15
-
-
0032189275
-
DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities
-
Levine C, Hiasa H, Marians KJ (1998) DNA gyrase and topoisomerase IV: Biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim Biophys Acta 1400(1-3): 29-43.
-
(1998)
Biochim Biophys Acta
, vol.1400
, Issue.1-3
, pp. 29-43
-
-
Levine, C.1
Hiasa, H.2
Marians, K.J.3
-
16
-
-
0034923502
-
DNA topoisomerases: Structure, function, and mechanism
-
Champoux JJ (2001) DNA topoisomerases: Structure, function, and mechanism. Annu Rev Biochem 70: 369-413.
-
(2001)
Annu Rev Biochem
, vol.70
, pp. 369-413
-
-
Champoux, J.J.1
-
17
-
-
0032508046
-
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
-
Cole ST, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685): 537-544.
-
(1998)
Nature
, vol.393
, Issue.6685
, pp. 537-544
-
-
Cole, S.T.1
-
18
-
-
33746819774
-
First functional characterization of a singly expressed bacterial type II topoisomerase: The enzyme from Mycobacterium tuberculosis
-
Aubry A, Fisher LM, Jarlier V, Cambau E (2006) First functional characterization of a singly expressed bacterial type II topoisomerase: The enzyme from Mycobacterium tuberculosis. Biochem Biophys Res Commun 348(1): 158-165.
-
(2006)
Biochem Biophys Res Commun
, vol.348
, Issue.1
, pp. 158-165
-
-
Aubry, A.1
Fisher, L.M.2
Jarlier, V.3
Cambau, E.4
-
19
-
-
77956343814
-
Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance
-
Wohlkonig A, et al. (2010) Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol 17(9): 1152-1153.
-
(2010)
Nat Struct Mol Biol
, vol.17
, Issue.9
, pp. 1152-1153
-
-
Wohlkonig, A.1
-
20
-
-
84863030593
-
Drug interactions with Bacillus anthracis topoisomerase IV: Biochemical basis for quinolone action and resistance
-
Aldred KJ, et al. (2012) Drug interactions with Bacillus anthracis topoisomerase IV: Biochemical basis for quinolone action and resistance. Biochemistry 51(1): 370-381.
-
(2012)
Biochemistry
, vol.51
, Issue.1
, pp. 370-381
-
-
Aldred, K.J.1
-
21
-
-
84877257450
-
Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: Mechanistic basis of quinolone resistance
-
Aldred KJ, McPherson SA, Turnbough CL, Jr, Kerns RJ, Osheroff N (2013) Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: Mechanistic basis of quinolone resistance. Nucleic Acids Res 41(8): 4628-4639.
-
(2013)
Nucleic Acids Res
, vol.41
, Issue.8
, pp. 4628-4639
-
-
Aldred, K.J.1
McPherson, S.A.2
Turnbough, C.L.3
Kerns, R.J.4
Osheroff, N.5
-
22
-
-
0031407768
-
DNA gyrase, topoisomerase IV, and the 4-quinolones
-
Drlica K, Zhao X (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61(3): 377-392.
-
(1997)
Microbiol Mol Biol Rev
, vol.61
, Issue.3
, pp. 377-392
-
-
Drlica, K.1
Zhao, X.2
-
23
-
-
0031728829
-
Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis
-
Li Z, et al. (1998) Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. Antimicrob Agents Chemother 42(12): 3293-3295.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, Issue.12
, pp. 3293-3295
-
-
Li, Z.1
-
24
-
-
0032705719
-
Mode of action of fluoroquinolones
-
Hooper DC (1999) Mode of action of fluoroquinolones. Drugs 58(suppl 2): 6-10.
-
(1999)
Drugs
, vol.58
, pp. 6-10
-
-
Hooper, D.C.1
-
25
-
-
0038650918
-
In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin
-
Price LB, et al. (2003) In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin. Antimicrob Agents Chemother 47(7): 2362-2365.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, Issue.7
, pp. 2362-2365
-
-
Price, L.B.1
-
26
-
-
59749085790
-
Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates
-
Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L (2009) Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother 53(1): 235-241.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, Issue.1
, pp. 235-241
-
-
Morgan-Linnell, S.K.1
Becnel Boyd, L.2
Steffen, D.3
Zechiedrich, L.4
-
27
-
-
79951956663
-
Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates
-
Bansal S, Tandon V (2011) Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates. Int J Antimicrob Agents 37(3): 253-255.
-
(2011)
Int J Antimicrob Agents
, vol.37
, Issue.3
, pp. 253-255
-
-
Bansal, S.1
Tandon, V.2
-
28
-
-
84858665539
-
A systematic review of gyrase mutations associated with fluoroquinolone- resistant Mycobacterium tuberculosis and a proposed gyrase numbering system
-
Maruri F, et al. (2012) A systematic review of gyrase mutations associated with fluoroquinolone- resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother 67(4): 819-831.
-
(2012)
J Antimicrob Chemother
, vol.67
, Issue.4
, pp. 819-831
-
-
Maruri, F.1
-
29
-
-
84891557923
-
Community-acquired pneumonia and tuberculosis: Differential diagnosis and the use of fluoroquinolones
-
Grossman RF, Hsueh PR, Gillespie SH, Blasi F (2014) Community-acquired pneumonia and tuberculosis: Differential diagnosis and the use of fluoroquinolones. Int J Infect Dis 18: 14-21.
-
(2014)
Int J Infect Dis
, vol.18
, pp. 14-21
-
-
Grossman, R.F.1
Hsueh, P.R.2
Gillespie, S.H.3
Blasi, F.4
-
30
-
-
65549120186
-
Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis
-
Long R, et al. (2009) Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis 48(10): 1354-1360.
-
(2009)
Clin Infect Dis
, vol.48
, Issue.10
, pp. 1354-1360
-
-
Long, R.1
-
31
-
-
68849086908
-
Fluoroquinolone resistance in Mycobacterium tuberculosis: The effect of duration and timing of fluoroquinolone exposure
-
Devasia RA, et al. (2009) Fluoroquinolone resistance in Mycobacterium tuberculosis: The effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 180(4): 365-370.
-
(2009)
Am J Respir Crit Care Med
, vol.180
, Issue.4
, pp. 365-370
-
-
Devasia, R.A.1
-
32
-
-
84890834354
-
Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions
-
Aldred KJ, et al. (2013) Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. ACS Chem Biol 8(12): 2660-2668.
-
(2013)
ACS Chem Biol
, vol.8
, Issue.12
, pp. 2660-2668
-
-
Aldred, K.J.1
-
33
-
-
84906877854
-
Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV
-
Aldred KJ, et al. (2014) Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. Biochemistry 53(34): 5558-5567.
-
(2014)
Biochemistry
, vol.53
, Issue.34
, pp. 5558-5567
-
-
Aldred, K.J.1
-
34
-
-
84959422266
-
Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis
-
Blower TR, Williamson BH, Kerns RJ, Berger JM (2016) Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. Proc Natl Acad Sci USA 113: 1706-1713.
-
(2016)
Proc Natl Acad Sci USA
, vol.113
, pp. 1706-1713
-
-
Blower, T.R.1
Williamson, B.H.2
Kerns, R.J.3
Berger, J.M.4
-
35
-
-
0036774642
-
Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv
-
Camus JC, Pryor MJ, Médigue C, Cole ST (2002) Re-annotation of the genome sequence of Mycobacterium tuberculosis H37Rv. Microbiology 148(pt 10): 2967-2973.
-
(2002)
Microbiology
, vol.148
, pp. 2967-2973
-
-
Camus, J.C.1
Pryor, M.J.2
Médigue, C.3
Cole, S.T.4
-
36
-
-
0029909110
-
Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrugresistant Mycobacterium tuberculosis
-
Xu C, Kreiswirth BN, Sreevatsan S, Musser JM, Drlica K (1996) Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrugresistant Mycobacterium tuberculosis. J Infect Dis 174(5): 1127-1130.
-
(1996)
J Infect Dis
, vol.174
, Issue.5
, pp. 1127-1130
-
-
Xu, C.1
Kreiswirth, B.N.2
Sreevatsan, S.3
Musser, J.M.4
Drlica, K.5
-
37
-
-
29944444255
-
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes
-
Aubry A, et al. (2006) Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes. Antimicrob Agents Chemother 50(1): 104-112.
-
(2006)
Antimicrob Agents Chemother
, vol.50
, Issue.1
, pp. 104-112
-
-
Aubry, A.1
-
38
-
-
33846897468
-
Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors
-
Tran TP, et al. (2007) Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors. Bioorg Med Chem Lett 17(5): 1312-1320.
-
(2007)
Bioorg Med Chem Lett
, vol.17
, Issue.5
, pp. 1312-1320
-
-
Tran, T.P.1
-
39
-
-
55849113010
-
Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones
-
German N, Malik M, Rosen JD, Drlica K, Kerns RJ (2008) Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones. Antimicrob Agents Chemother 52(11): 3915-3921.
-
(2008)
Antimicrob Agents Chemother
, vol.52
, Issue.11
, pp. 3915-3921
-
-
German, N.1
Malik, M.2
Rosen, J.D.3
Drlica, K.4
Kerns, R.J.5
-
40
-
-
70349126269
-
Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV
-
Pan XS, Gould KA, Fisher LM (2009) Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV. Antimicrob Agents Chemother 53(9): 3822-3831.
-
(2009)
Antimicrob Agents Chemother
, vol.53
, Issue.9
, pp. 3822-3831
-
-
Pan, X.S.1
Gould, K.A.2
Fisher, L.M.3
-
41
-
-
77953780481
-
Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones
-
Oppegard LM, et al. (2010) Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones. Antimicrob Agents Chemother 54(7): 3011-3014.
-
(2010)
Antimicrob Agents Chemother
, vol.54
, Issue.7
, pp. 3011-3014
-
-
Oppegard, L.M.1
-
42
-
-
79955546959
-
Fluoroquinolone and quinazolinedione activities against wildtype and gyrase mutant strains of Mycobacterium smegmatis
-
Malik M, et al. (2011) Fluoroquinolone and quinazolinedione activities against wildtype and gyrase mutant strains of Mycobacterium smegmatis. Antimicrob Agents Chemother 55(5): 2335-2343.
-
(2011)
Antimicrob Agents Chemother
, vol.55
, Issue.5
, pp. 2335-2343
-
-
Malik, M.1
-
43
-
-
0031753298
-
Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance
-
Dong Y, Xu C, Zhao X, Domagala J, Drlica K (1998) Fluoroquinolone action against mycobacteria: Effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 42(11): 2978-2984.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, Issue.11
, pp. 2978-2984
-
-
Dong, Y.1
Xu, C.2
Zhao, X.3
Domagala, J.4
Drlica, K.5
-
44
-
-
0033011810
-
Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8methoxyl group on survival in liquid media and in human macrophages
-
Zhao BY, Pine R, Domagala J, Drlica K (1999) Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 43(3): 661-666.
-
(1999)
Antimicrob Agents Chemother
, vol.43
, Issue.3
, pp. 661-666
-
-
Zhao, B.Y.1
Pine, R.2
Domagala, J.3
Drlica, K.4
-
45
-
-
0032168167
-
Etoposide: Four decades of development of a topoisomerase II inhibitor
-
Hande KR (1998) Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 34(10): 1514-1521.
-
(1998)
Eur J Cancer
, vol.34
, Issue.10
, pp. 1514-1521
-
-
Hande, K.R.1
-
47
-
-
84896931441
-
Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase
-
Kumar R, Madhumathi BS, Nagaraja V (2014) Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase. Antimicrob Agents Chemother 58(4): 2013-2020.
-
(2014)
Antimicrob Agents Chemother
, vol.58
, Issue.4
, pp. 2013-2020
-
-
Kumar, R.1
Madhumathi, B.S.2
Nagaraja, V.3
-
48
-
-
0030958484
-
Spontaneous DNA lesions poison human topoisomerase IIa and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints
-
Kingma PS, Greider CA, Osheroff N (1997) Spontaneous DNA lesions poison human topoisomerase IIa and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry 36(20): 5934-5939.
-
(1997)
Biochemistry
, vol.36
, Issue.20
, pp. 5934-5939
-
-
Kingma, P.S.1
Greider, C.A.2
Osheroff, N.3
-
49
-
-
0033598702
-
DNA topoisomerases as targets for the anticancer drug TAS- 103: DNA interactions and topoisomerase catalytic inhibition
-
Fortune JM, et al. (1999) DNA topoisomerases as targets for the anticancer drug TAS- 103: DNA interactions and topoisomerase catalytic inhibition. Biochemistry 38(47): 15580-15586.
-
(1999)
Biochemistry
, vol.38
, Issue.47
, pp. 15580-15586
-
-
Fortune, J.M.1
-
50
-
-
0032504157
-
Merbarone inhibits the catalytic activity of human topoisomerase IIa by blocking DNA cleavage
-
Fortune JM, Osheroff N (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIa by blocking DNA cleavage. J Biol Chem 273(28): 17643-17650.
-
(1998)
J Biol Chem
, vol.273
, Issue.28
, pp. 17643-17650
-
-
Fortune, J.M.1
Osheroff, N.2
-
51
-
-
79953901930
-
Interactions between the etoposide derivative F14512 and human type II topoisomerases: Implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage
-
Gentry AC, et al. (2011) Interactions between the etoposide derivative F14512 and human type II topoisomerases: Implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry 50(15): 3240-3249.
-
(2011)
Biochemistry
, vol.50
, Issue.15
, pp. 3240-3249
-
-
Gentry, A.C.1
|